Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma
Technology appraisal guidance
Reference number: TA661
Published:
Topic title changed from 'Pembrolizumab for treating recurrent or metastatic squamous cell head and neck cancer', to 'Pembrolizumab for untreated metastatic or unresectable recurrent squamous cell head and neck cancer'.